ClinicalTrials.Veeva

Menu

A Study on the Regenerative Treatment of Tympanic Membrane With NPC-18 and FBG-18

T

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Status and phase

Completed
Phase 3

Conditions

Tympanic Membrane Perforation

Treatments

Drug: fiblast,gelatin sponge,fibrin glue

Study type

Interventional

Funder types

Other

Identifiers

NCT02550314
TRIENT1328

Details and patient eligibility

About

To assess the efficacy and safety of the regeneration treatment of tympanic membrane with NPC-18 and FBG-18.

Enrollment

20 patients

Sex

All

Ages

20 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Written informed concent obtained
  2. At the time of obtaining informed consent, Ages ranged from over 20 to 80
  3. At the time of obtaining informed consent, only those with tympanic membrane perforation in 1 ear (not both) for over 6 months (perforation in both ears is excluded)

Exclusion criteria

  1. TMP caused by burn or radiation therapy
  2. In patients with chronic otitis media with ear drum perforation, tympanic cavity are not dry
  3. Inflammatory,infection or otorrhea in patient's eardrum,earcanal,middle ear and tympanic cavity
  4. No invasion of epithelial and no cholesteatoma in tympanic cavity or around perforated edge
  5. History of tympanoplasty
  6. A Part of the eardrum adhered to tympanic cavity
  7. By temporal bone CT, soft tissue shadow in mastoid antrum or tympanic (using a CT image of less than 12 wks before patients registration)
  8. Abnormality in the chain and ear ossicles
  9. Air-bone gap difference more than 25dB by patch hearing test
  10. Unable to see whole edge of TMP due to narrow external auditory canal
  11. Unable to wash out Ear drops during the treatment period
  12. Presenting with uncontrolled diabetes (NGSP HbA1c 6.9% and more)
  13. Presenting with autoimmune disease
  14. History of malignancy within 3 years prior to obtained informed concent
  15. Administration of immunosuppressive agent or anti-cancer-agent
  16. History of Allergic reaction to local anesthetic(Xylocaine), bFGF(Fiblast spray), fibrin glue(Beriplast P Combi set, etc.), gelatin sponge formulation(spongel) and others
  17. Though out the period from screening to treatment, patient who is unable to wash out "Thrombolytic agent", "Anticoagulant", "Anti-platelet agent", "Procoagulant agent", "anti-line solvent"and"aprotinin formulation"

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

20 participants in 1 patient group

NPC-18,FBG-18
Experimental group
Description:
Intervention drug: NPC-18;trafermin(recombination) and gelatin spnge, combination drug FBG-18;fibrin glue Usage:NPC-18 and FBG-18 is administered at the same time for regenerative treatment of tympanic membrane
Treatment:
Drug: fiblast,gelatin sponge,fibrin glue

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems